165 related articles for article (PubMed ID: 23381694)
1. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
[TBL] [Abstract][Full Text] [Related]
2. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
4. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
[TBL] [Abstract][Full Text] [Related]
5. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Schelman WR; Liu G; Wilding G; Morris T; Phung D; Dreicer R
Invest New Drugs; 2011 Feb; 29(1):118-25. PubMed ID: 19763400
[TBL] [Abstract][Full Text] [Related]
8. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
Wu Y; Shao N; Shen ZX; Li Q; Wang Y; Li C; Ma G; Dong J; Lu XJ; Feng NH
Eur Rev Med Pharmacol Sci; 2014; 18(21):3291-6. PubMed ID: 25487941
[TBL] [Abstract][Full Text] [Related]
10. Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
Clarkson-Jones JA; Kenyon AS; Kemp J; Lenz EM; Oliver SD; Swaisland H
Xenobiotica; 2012 Apr; 42(4):363-71. PubMed ID: 22014279
[TBL] [Abstract][Full Text] [Related]
11. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Qi P; Chen M; Zhang LX; Song RX; He ZH; Wang ZP
PLoS One; 2015; 10(7):e0133803. PubMed ID: 26192308
[TBL] [Abstract][Full Text] [Related]
12. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Sternberg C; Armstrong A; Pili R; Ng S; Huddart R; Agarwal N; Khvorostenko D; Lyulko O; Brize A; Vogelzang N; Delva R; Harza M; Thanos A; James N; Werbrouck P; Bögemann M; Hutson T; Milecki P; Chowdhury S; Gallardo E; Schwartsmann G; Pouget JC; Baton F; Nederman T; Tuvesson H; Carducci M
J Clin Oncol; 2016 Aug; 34(22):2636-43. PubMed ID: 27298414
[TBL] [Abstract][Full Text] [Related]
15. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R
J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).
Dawson N; Payne H; Battersby C; Taboada M; James N
J Cancer Res Clin Oncol; 2011 Jan; 137(1):99-113. PubMed ID: 20390429
[TBL] [Abstract][Full Text] [Related]
19. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
20. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
